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Cathepsin-S degraded decorin are elevated
in fibrotic lung disorders – development
and biological validation of a new serum
biomarker
S.N. Kehlet1,4*, C.L. Bager2, N. Willumsen1, B. Dasgupta3, C. Brodmerkel3, M. Curran3, S. Brix4, D.J. Leeming1
and M. A. Karsdal1
Abstract
Background: Decorin is one of the most abundant proteoglycans of the extracellular matrix and is mainly secreted
and deposited in the interstitial matrix by fibroblasts where it plays an important role in collagen turnover and
tissue homeostasis. Degradation of decorin might disturb normal tissue homeostasis contributing to extracellular
matrix remodeling diseases. Here, we present the development and validation of a competitive enzyme-linked
immunosorbent assay (ELISA) quantifying a specific fragment of degraded decorin, which has potential as a novel
non-invasive serum biomarker for fibrotic lung disorders.
Methods: A fragment of decorin cleaved in vitro using human articular cartilage was identified by mass-spectrometry
(MS/MS). Monoclonal antibodies were raised against the neo-epitope of the cleaved decorin fragment and a competitive
ELISA assay (DCN-CS) was developed. The assay was evaluated by determining the inter- and intra-assay precision,
dilution recovery, accuracy, analyte stability and interference. Serum levels were assessed in lung cancer patients,
patients with idiopathic pulmonary fibrosis (IPF), patients with chronic obstructive pulmonary disease (COPD) and
healthy controls.
Results: The DCN-CS ELISA was technically robust and was specific for decorin cleaved by cathepsin-S. DCN-CS
was elevated in lung cancer patients (p < 0.0001) and IPF patients (p < 0.001) when compared to healthy
controls. The diagnostic power for differentiating lung cancer patients and IPF patients from healthy controls
was 0.96 and 0.77, respectively.
Conclusion: Cathepsin-S degraded decorin could be quantified in serum using the DCN-CS competitive ELISA.
The clinical data indicated that degradation of decorin by cathepsin-S is an important part of the pathology of
lung cancer and IPF.
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Background
Idiopathic pulmonary fibrosis (IPF), chronic obstructive
pulmonary disease (COPD) and lung cancer are lung
pathologies which are characterized by excessive accu-
mulation of extracellular matrix (ECM) leading to loss of
tissue homeostasis and progressive disease phenotype
[1–3]. Biomarkers which reflect these processes may
therefore play an important role in identifying patients
with rapid disease progression. Decorin is a member of
the small leucine-rich proteoglycan (SLRP) family and is
one of the most abundant proteoglycans of the intersti-
tial matrix. The protein is mainly secreted and deposited
by fibroblasts. It consists of a single covalently attached
N-terminal glycosaminoglycan (GAG) chain, composed
of either dermatan or chondroitin sulfate, and 12
leucine-rich tandem repeats representing the protein
core [4–6].
Due to its diverse ECM protein binding partners and
its regulation of cell growth and cell differentiation, de-
corin has been named as “the guardian from the matrix”
[7] recognizing the significance of decorin in tissue
homeostasis. The main ECM binding partners are fibril-
lar collagens (type I, II, III and VI) and decorin has
shown to play a role in the regulation of fibrillogenesis
and stabilization of fibrils, and may act as a central
player in collagen assembly/turnover and consequently
tissue homeostasis [8, 9]. Supporting this, decorin
knock-out in mice results in abnormal collagen fibril for-
mation and enhanced collagen degradation [10].
In addition to playing a role in collagen fibril forma-
tion in the interstitial ECM, decorin sequesters multiple
growth factors, such as TGF-beta and directly antago-
nizes several members of the receptor tyrosine kinase
family, including the epidermal growth factor receptor
(EGFR) and insulin-like growth factor receptor I (IGF-
IR) [7, 11–14]. As a consequence, decorin regulates sur-
vival, migratory, proliferative and angiogenic signaling
pathways.
Decorin’s ability to modulate various signal transduc-
tion pathways has given it a valid reputation within can-
cer and several studies have revealed decorin as a tumor
repressor which counteracts tumorigenic and angiogenic
growth [15]. Furthermore, reduced decorin within the
tumor stroma is a poor prognostic factor of invasive
breast-, lung- and soft tissue cancers as well as in mye-
loma [5, 16–18].
Decorin appears to have a protective role in cancer and
has also been shown to have anti-fibrotic properties. Fi-
brosis is characterized by an increased and disorganized
deposition of ECM proteins resulting in loss of tissue and
organ function. One of the key pro-fibrotic mediators is
TGF-beta, a chemotactic factor for fibroblasts enhancing
the synthesis of ECM proteins. As decorin is an inhibitor
of TGF-beta, numerous studies have investigated the
decorin’s potential to block the fibrotic response and de-
corin has shown to reduce tissue fibrosis in kidney and
lung in multiple disease models [19–21].
Increased ECM remodeling and protease-mediated
degradation of ECM proteins is a well-documented and
significant component of cancer pathology and lung
fibrosis [1–3, 22]. We hypothesize that degradation of
decorin may have biomarker potential in these patholo-
gies as degradation of decorin might inactivate and dis-
rupt its anti-tumor and anti-fibrotic capabilities.
A decorin fragment was previously identified in hu-
man knee articular cartilage using mass spectrometry
(MS/MS) [23]. The aim of this work was to develop a
competitive enzyme-linked immunosorbent assay (ELISA)
targeting the specific degraded fragment of decorin, iden-
tify the protease generating this fragment, and to investi-
gate the biomarker potential of this fragment in serum
from patients with various lung pathologies.
Methods
Selection of peptides
The following cleavage site (↓) on decorin was previously
identified in human knee articular cartilage using mass
spectrometry and published by Zhen et al. [23]:
72LDK↓VPKDLPPDTT84 located in the first leucine rich
repeat of the protein.
In order to generate an antibody specific for the N-
terminal of the cleavage fragment, a sequence of 10
amino acids adjacent to the site was chosen as the tar-
get: ↓75VPKDLPPDTT84. This amino acid sequence was
used to design the standard peptide. The sequence was
blasted for homology to other human secreted extra-
cellular matrix proteins using NPS@: Network Protein
Sequence Analysis with the UniprotKB/Swiss-prot
database [24].
Synthetic peptides used for monoclonal antibody pro-
duction and validation of the ELISA assay were purchased
from Chinese Peptide Company (Hangzhou, China) and
Genscript (Piscataway, NJ, USA) and shown in Table 2. A
biotinylated peptide (VPKDLPPDTT-biotin) was included
as a coating peptide on streptavidin-coated ELISA plates.
The specificity of the antibody was tested by including
an elongated standard peptide with an additional amino
acid added to the N-terminal of the peptide sequence
(KVPKDLPPDTT), as well as a non-sense standard peptide
(DSSAPKAAQA) and a non-sense biotinylated coating
peptide (biotin-DSSAPKAAQA) in the assay validation.
The immunogenic peptide (VPKDLPPDTT-KLH) was
generated by covalently cross-linking the standard peptide
to Keyhole Limpet Hemocyanin (KLH) carrier protein
using Succinimidyl 4-(N-maleimidomethyl)cyclohexane-1-
carboxylate, SMCC (Thermo Scientific, Waltham, MA,
USA, cat.no. 22336).
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Monoclonal antibody production
Four to six week old Balb/C mice were immunized by sub-
cutaneous injection of 200 μL emulsified antigen contai-
ning 50 μg immunogenic peptide (VPKDLPPDTT-KLH)
mixed with Freund’s incomplete adjuvant (Sigma-Aldrich,
St. Louis, MO, USA). Consecutive immunizations were
performed at 2-week intervals until stable sera titer levels
were reached. The mouse with the highest titer rested for
four weeks and was then boosted with 50 μg immunogenic
peptide in 100 μL 0.9% NaCl solution intravenously. Hy-
bridoma cells were produced by fusing spleen cells with
SP2/0 myeloma cells as previously described [25]. The
resultant hybridoma cells were then cultured in 96-well
microtiter plates and standard limited dilution was used
to secure monoclonal growth. The supernatants were
screened for reactivity using the biotinylated peptide
(VPKDLPPDTT-biotin) as coating agent in the com-
petitive immunoassays.
Clone characterization
The reactivity of the monoclonal antibodies was evalu-
ated by displacement using human serum samples and
the standard peptide (VPKDLPPDTT) in a preliminary
ELISA using 10 ng/mL biotinylated coating peptide
on streptavidin-coated microtiter plates (Roche, Basel,
Switzerland, cat. #11940279) and the supernatant
from the antibody producing monoclonal hybridoma
cells. The clone with the best reactivity towards the
standard peptide was purified using protein-G-columns ac-
cording to the manufacturer’s instructions (GE Healthcare
Life Sciences, Little Chalfont, UK, cat. #17–0404-01).
Cleavage of decorin in vitro
Reconstituted human recombinant decorin (ACRO Biosys-
tems, Newark, DE, USA, cat. # DE1-HS223) was diluted to
a final concentration of 100 μg/mL in cathepsin buffer
(100 mM sodium phosphate, 2 mM DTT, 0.01% Brij-35,
pH 7.4), MMP-buffer (50 mM Tris-HCL, 200 mM NaCl,
10 mM CaCl2, 100 μM ZnAc, pH 7.5) or ADAMTS-5
buffer (50 mM Tris, 100 mM NaCl, 5 mM CaCl2, 0.05%
Brij-35, pH 7.5). The solutions incubated at 37 °C for 1 h,
24 h and 72 h with or without the addition of the following
proteases: Cathepsin-S (Merckmillipore, cat. # 219343),
cathepsin-L (Merckmillipore, cat. # 219402), APMA acti-
vated MMP-2 (Biocol, cat. # II.5), MMP-9 (Giotto, cat. #
G04MP09C) and ADAMTS-5 (R&D systems, cat. # 2198-
AD). Cathepsins and MMPs were added to a final concen-
tration of 2 μg/mL and ADAMTS-5 to a final concentra-
tion of 10 μg/mL. A positive control protein with known
cleavage by the above proteases was included. The reaction
was stopped by adding E-64 (final concentration of 1 uM)
to cathepsins solutions and EDTA to the MMP solutions
(final concentration of 1 uM) and ADAMTS-5 solutions
(final concentration of 5 uM). Cathepsin-, MMP- and
ADAMTS-5 buffer with relevant proteases were included
as controls. Samples were stored at −80 °C until ana-
lysis. The cleavage of decorin was confirmed by silver-
staining according to the manufacturer’s instructions
(SilverXpress®, Invitrogen, cat. #LC6100) and coomassie
blue (data not shown).
DCN-CS (decorin degraded by cathepsin-S) ELISA protocol
Optimal incubation -buffer, −time and -temperature, as
well as the optimal concentrations of antibody and coa-
ting peptide were determined and the finalized DCN-CS
competitive ELISA protocol was as follows:
A 96-well streptavidin-coated microtiter plate was
coated with 2.5 ng/mL biotinylated coating peptide dis-
solved in assay buffer (50 mM Tris-BTB, 4 g/L NaCl,
pH 8.0) and incubated for 30 min. at 20 °C in darkness
shaking (300 rpm). Twenty μL standard peptide or pre-
diluted serum (1:4) were added to appropriate wells,
followed by the addition of 100 μL monoclonal antibody
dissolved in assay buffer to a concentration of 30 ng/mL
to each well and incubated 20 h at 5 °C in darkness shak-
ing (300 rpm). One hundred μL of goat anti-mouse POD-
conjugated IgG antibody (Thermo Scientific, Waltham,
MA, USA, cat. #31437) diluted 1:6000 in assay buffer to
obtain a final concentration of 130 ng/mL was added to
each well and incubated 1 h at 20 °C in darkness shaking.
All incubation steps were followed by five washes in wash-
ing buffer (20 mM Tris, 50 mM NaCl, pH 7.2). Finally,
100 μL tetramethylbenzidine (TMB) (cat. 438OH, Kem-
En-Tec Diagnostics, Denmark) was added to each well
and the plate was incubated for 15 min at 20 °C in
darkness shaking. The enzymatic reaction was stopped
by adding 0.18 M H2SO4 and absorbance was mea-
sured at 450 nm with 650 nm as reference. A calibra-
tion curve was plotted using a 4-parameter logistic
curve fit. Data were analyzed using the SoftMax Pro
v.6.3 software.
Technical evaluation of the DCN-CS ELISA
To evaluate the technical performance of the DCN-CS
ELISA, the following validation tests were carried out:
Inter- and intra-assay variation, linearity, lower limit of
detection, upper limit of detection, lower limit of quanti-
fication, analyte stability (freeze/thaw and storage) and
interference.
The inter- and intra-assay variation was determined by
ten independent runs on different days using ten quality
control samples covering the detection range, with each
run consisting of double-determinations of the samples.
The ten quality control samples consisted of: two human
serum samples, one sheep serum sample, one fetal calve
serum sample, four human serum samples spiked with
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standard peptide and two samples with standard peptide
in buffer. Intra-assay variation was calculated as the
mean coefficient of variance (CV%) within plates and
the inter-assay variation was calculated as the mean
CV% between the ten individual runs. To assess linearity
of the assay, two-fold dilutions of human serum samples
were performed and dilution linearity was calculated as
a percentage of recovery of the un-diluted sample. The
lower limit of detection (LLOD) was determined from
21 measurements using assay buffer as sample and was
calculated as the mean + three standard deviations. The
upper limit of detection (ULOD) was determined from
ten independent runs of the highest standard peptide
concentration and was calculated as the mean back-
calibration calculation + three standard deviations. The
lower limit of quantification (LLOQ) was determined
from three independent runs of a serum sample diluted
stepwise and determined as the highest DCN-CS level
quantifiable in serum with a coefficient of variation
below 30%. Analyte stability was first determined by the
effect of repeated freeze/thaw of serum samples by
measuring the DCN-CS level in three human serum
samples in four freeze/thaw cycles. The freeze/thaw re-
covery was calculated with the first cycle as reference.
Second, analyte stability in relation to storage was deter-
mined by a 24 h study performed at 4 °C or 20 °C. The
DCN-CS level in three human serum samples was mea-
sured after 0 h, 2 h, 4 h and 24 h of storage and recovery
was calculated with samples stored at −20 °C as refe-
rence. Interference was determined by adding a low/high
content of hemoglobin (0.155/0.310 mM), lipemia/lipids
(4.83/10.98 mM) and biotin (30/90 ng/mL) to a serum
sample of known concentration. Recovery percentage
was calculated with the normal serum sample as reference.
Clinical validation of DCN-CS
Patient serum samples consisted of three different cohorts.
Cohort 1 was obtained from the commercial vendor Pro-
teoGenex (Culver City, CA, USA) and included patients
with non-small cell lung cancer (NSCLC), IPF, COPD and
colonoscopy-negative controls with no symptomatic or
chronic disease. A panel of healthy donors acquired from
the commercial vendor Valley Biomedical (Winchester,
VA, USA) were included as controls (Table 1).
Cohort 2 consisted of lung cancer patients acquired
from the commercial vendor Asterand (Detroit, MI,
USA) and healthy control serum samples obtained from
a Danish study population.
Cohort 3 was a combination of serum samples from
patients diagnosed with IPF (baseline samples, CTgov
reg. NCT00786201) and healthy control serum samples
acquired from the commercial vendor Valley Biomedical
(Winchester, VA, USA) (Table 1).
Statistical analysis
The level of DCN-CS in serum samples was compared
using one-way ANOVA adjusted for Tukey’s multiple
comparisons test (parametric data), Kruskal-Wallis ad-
justed for Dunn’s multiple comparisons test (non-para-
metric data) or unpaired, two-tailed Mann-Whitney test.
D’Agostino-Pearson omnibus test was used to assess the
normality of the data. The diagnostic power was inves-
tigated by the area under the receiver operating cha-
racteristics (AUROC). Sensitivity and specificity were
determined for cut-off values based on the ROC curves.
The cut-off values should be regarded as a preliminary
estimated cut-off point applied to achieve the reported
maximized sensitivity and specificity.
Unless otherwise stated, data are shown as Tukey box
plots, where the boxes represent the 25th, 50th and 75th
percentiles. The whiskers represent the lowest and highest
value, except outliers, which are higher than 1.5 times the
75th percentile or lower than 1.5 times the 25th percen-
tile. P-values <0.05 were considered significant. Statistical
analyses were performed using GraphPad Prism version
6 (GraphPad Software, Inc., CA, USA) and MedCalc
Statistical Software version 12 (MedCalc Software, Ostend,
Belgium). Graphs were designed using GraphPad Prism
version 6 (GraphPad Software, Inc., CA, USA).
Results
Specificity of the DCN-CS ELISA assay
The target sequence, 75VPKDLPPDTT84, was blasted for
homology to other human secreted extracellular matrix
proteins using NPS@: Network Protein Sequence Ana-
lysis with the UniprotKB/Swiss-prot database. The target
sequence was found to be unique to human decorin
when compared to other secreted ECM proteins. Allow-
ing one amino acid mismatch, two secreted extracellular
matrix proteins, Wnt-11 and Podocan, were identified
with mismatches at the 6th and 4th position, respectively
(Table 2). There was no reactivity against the sequence
of Wnt-11, whereas some reactivity was observed against
Podocan (data not shown). However, the affinity of the
antibody was approximately 10 times higher for decorin
than the podocan peptide. At the same time, it is un-
known whether podocan will be cleaved in vivo between
the exact two amino acids creating this peptide frag-
ment. Furthermore, decorin has been shown to be the
most abundant proteoglycan in human adult skin [6] de-
creasing the likelihood of reactivity towards podocan in
biological samples.
The specificity of the competitive DCN-CS ELISA was
evaluated by analyzing the reactivity towards the standard
peptide, a non-sense peptide, an elongated peptide and
using a non-sense biotinylated coating peptide. All peptide
sequences are shown in Table 2 and results are shown in
Fig. 1. The antibody only reacted with the standard peptide
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and the standard peptide clearly inhibited the signal in a
dose-dependent manner compared to the other peptides.
No detectable signal was observed when using the non-
sense biotinylated coating peptide. These data suggest that
the selected antibody exhibits high epitope specificity.
Degradation by Cathepsin-S
The ability of different proteases to generate the spe-
cific decorin fragment was investigated by incubating
recombinant human decorin with cathepsin-S (Cat-S),
Cathepsin-L (Cat-L), MMP-2, MMP-9 and ADAMTS-5.
As shown in Fig. 2, Cat-S was able to generate decorin
fragments in a time-dependent manner. Almost 6-fold
higher decorin fragments were detected after incubating
recombinant decorin with Cat-S for 24 h. No cleavage was
observed with Cat-L, MMP-9, MMP-2 and ADAMTS-5
up to 72 h of incubation (data not shown).
Together, these results show that Cat-S can generate
the target peptide recognized by the antibody.
Technical evaluation of the DCN-CS ELISA assay
A series of technical validations were performed to
further evaluate the DCN-CS ELISA. The different
validation steps and DCN-CS performance are shown
in Table 3. The measuring range (LLOD to ULOD) of
the assay was determined to 1.2–345.3 ng/mL and
the lower limit of quantification (LLOQ) was 5.3 ng/
mL. The intra- and inter-assay variation was 3 and
13%, respectively. The acceptance criterion was below
10% for the intra-assay variation and below 15% for
the inter-assay variation and therefore acceptable. Human
serum needed to be diluted 1:4 to obtain linearity and
mean dilution recovery for pre-diluted human serum was
100%. The analyte recovery in serum was 94% after 4
freeze/thaw cycles and after storage at 4 °C for 24 h the
recovery was 87%. The acceptance criterion was a reco-
very within 100% ± 20%. Analyte stability was also tested
at 20 °C for 2, 4 and 24 h. The recovery after 2 and 4 h
was 93% and 78%, respectively. However after 24 h the
analyte could not be recovered within the acceptance
range (53% recovery). These data indicate that the analyte
in serum is stable at 4 °C and serum samples to be ana-
lyzed for DCN-CS should not be stored above this
temperature for more than four hours. No interference
was detected from either low or high contents of biotin,
lipids or hemoglobin with recoveries ranging from 86 to
107%. The acceptance criterion was a recovery within
100% ± 20%.
Clinical evaluation – DCN-CS as a biomarker for fibrotic
lung disorders
DCN-CS were measured in serum samples from three
independent cohorts including patients with lung cancer,
IPF, COPD and healthy controls. The data are presented
in Fig. 3. Results from cohort 1 show that DCN-CS was
significantly elevated in serum from NSCLC (p < 0.0001)
and IPF (p < 0.001) patients as compared to healthy con-
trols. No significance was observed for COPD patients.
The mean level of DCN-CS was also significantly higher
in NSCLC patients compared to colonoscopy-negative
Table 2 Synthetic peptides used for development and validation
of the DCN-CS ELISA assay
Peptide name Amino acid sequence
Selection/standard peptide VPKDLPPDTT
Immunogenic peptide VPKDLPPDTT-KLH
Biotinylated coating peptide VPKDLPPDTT-biotin
Elongated peptide KVPKDLPPDTT
Non-sense selection peptide DSSAPKAAQA
Non-sense coating peptide biotin-DSSAPKAAQA
Wnt-11 peptide VPKDLDIRPV
Podocan peptide VPKHLPPALY
Table 1 Clinical sample overview and patients demographics
Cohort Samples No. of
subjects
Mean age
(range)
Gender, %
females
Tumor
stage I
Tumor
stage II
Tumor
stage III
Tumor
stage IV
1 NSCLC patients 8 61 (47–77) 12.8 1 2 3 2
1 IPF patients 8 74 (55–82) 62.5 - - - -
1 COPD patients 8 75 (69–82) 50.0 - - - -
1 Colonoscopy-negative controls 8 55 (44–65) 75.0 - - - -
1 Healthy controls 20 34 (20–51) 10.0 - - - -
2 NSCLC patientsa 12 60 (47–80) 25.0 5 2 4 -
2 SCLC patients 8 61 (54–82) 25.0 3 1 4 -
2 Healthy controls 43 71 (60–82) 100.0 - - - -
3 IPF patients 116 65 (43–80) 21.5 - - - -
3 Healthy controls 38 34 (20–58) 10.5 - - - -
aNo tumor stage information of one patient
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controls, IPF and COPD patients. Data from cohort 2
confirmed the findings from cohort 1: DCN-CS was
significantly elevated in NSCLC and SCLC patients as
compared to healthy controls (p < 0.0001). Cohort 3
included patients with IPF and confirmed the results
observed in cohort 1; IPF patients had a significantly
higher level of DCN-CS (p < 0.0001) as compared to
healthy controls.
The area under the receiver operating characteristics
(AUROC) was used to evaluate the discriminative power
of DCN-CS in relation to NSCLC and IPF. NSCLC pa-
tients, IPF patients and healthy controls from all cohorts
were pooled and grouped into ‘NSCLC’, ‘IPF’ and ‘healthy
controls’. As shown in Table 4, DCN-CS was able to dis-
criminate between NSCLC patients and healthy controls
with an AUROC of 0.96 (95%CI: 0.90–0.99), p < 0.0001)
with a specificity of 100% and sensitivity of 90% for an es-
timated optimal cut-off value. Similarly, DCN-CS was able
to identify IPF patients from healthy controls with an
AUROC of 0.77 (95%CI: 0.71–0.83), p < 0.0001) with a
specificity of 83% and sensitivity of 63% for an estimated
optimal cut-off. The ROC curves are presented in Fig. 4.
These findings indicate that DCN-CS levels are able to
separate patients with NSCLC and IPF from healthy
controls with high diagnostic accuracy. Thus this specific
fragment in serum has biomarker potential in fibrotic
lung disorders such as lung cancer and IPF.
Discussion
The present study describes the development and bio-
logical validation of a technically robust competitive
ELISA assay quantifying a Cat-S degraded fragment of
decorin in serum. The main findings of this study were:
1) the fragment was significantly elevated in lung cancer
and IPF patients compared to healthy controls 2) the
fragment was detectable in serum and 3) the assay was
technically robust and specific towards a unique Cat-S de-
graded fragment of decorin, DCN-CS. To our knowledge
Fig. 1 Specificity of the DCN-CS monoclonal antibody. Monoclonal antibody reactivity towards the standard peptide (VPKDLPPDTT), the elongated
peptide (KVPKDLPPDTT), a non-sense peptide (DSSAPKAAQA) and a non-sense coating peptide (biotin-DSSAPKAAQA) was tested for in the competitive
DCN-CS ELISA assay. Signals are shown as optical density (OD) at 450 nm (subtracted the background at 650 nm) as a function of peptide concentration
Fig. 2 Cleavage of decorin by Cathepsin-S. Degraded decorin
levels were measured after 1 h and 24 h incubation of human
recombinant decorin with Cathepsin-S. Data were normalized
by subtracting the background measured in buffer alone. The
experiment was repeated twice and data are shown as the mean
of the two replicates with standard deviation
Table 3 Technical validation data of the DCN-CS ELISA assay
Tecnical validation step DCN-CS performance
Detection range (LLOD-ULOD) 1.2–345.3 ng/mL
Lower limit of quantification (LLOQ) 5.3 ng/mL
Intra-assay variation 3%
Inter-assay variation 13%
Dilution of serum samples 1:4
Dilution recovery (1:4 pre-dilution)a 100% (82–113%)
Freeze/thaw recovery (4 cycles)a 94% (90–97%)
Analyte stability up to 24 h, 4 °Ca 87% (86–90%)
Interference Lipids, low/high 107%/86%
Interference Biotin, low/high 100%/100%
Interference Hemoglobin, low/high 100%/100%
aPercentages are reported as mean with range shown in brackets
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this is the first biological validation of a specific decorin
fragment in fibrotic lung disorders.
Decorin has been shown to play a protective role in
cancer and fibrosis due to its ability to modulate various
signal transduction pathways and sequester TGF-beta
via direct binding [5]. This has led to the speculation
that degradation of decorin may induce the development
of cancer and fibrotic diseases by disrupting the binding
to its binding partners. The lungs are an organ with a
large amount of interstitial matrix and we have shown
that patients with fibrotic lung disorders, such as cancer
and IPF, have an increased level of degraded decorin.
Cat-S is produced in both tumor cells and tumor-
associated macrophages and has been associated with
growth, angiogenesis and metastasis in different cancer
types [26–28]. The interaction between these two pro-
teins might give rise to a certain pathology where the
interstitial matrix is involved and this interaction can be
measured by the assay presented here.
The data suggest that Cat-S specific degradation of
decorin has a relevant role in the pathology of lung can-
cer and IPF. We hypothesize that increased degradation
of decorin triggers a fibrotic response both by inhibiting
binding of TGF-beta to decorin which will result in the
release of excessive amounts of TGF-beta but also by
disrupting proper collagen fibril formation leading to loss
of homeostasis in the interstitial matrix. Several studies
have shown that disrupting the normal collagen turnover
balance leads to fibrosis and cancer [1–3, 22]. Why the
specific decorin fragment was not significantly elevated in
patients with COPD is to be investigated further.
Based on the high elevated level of degraded decorin
in patients compared to healthy controls, the present
assay can provide a novel non-invasive clinical tool in
Fig. 3 Serum DCN-CS levels in patients with fibrotic lung disorders. Serum DCN-CS was assessed in three independent cohorts: Cohort 1 included
patients with NSCLC (n = 8), IPF (n = 8), COPD (n = 8), colonoscopy-negative controls (CNC) (n = 8) and a panel of healthy controls (HC) (n = 20).
Data were compared using one-way ANOVA adjusted for Tukey’s multiple comparisons test. Cohort 2 consisted of patients with NSCLC (n = 12),
SCLC (n = 8) and healthy controls (HC) (n = 43). Data were compared using Kruskal-Wallis adjusted for Dunn’s multiple comparisons test. Cohort
3 comprised serum samples from patients diagnosed with IPF (n = 116) and healthy controls (HC) (n = 38). Groups were compared using unpaired,
two-tailed Mann-Whitney test. Data are shown as Tukey box plots. Significance levels: ***: p < 0.001 and ****: p < 0.0001
Table 4 Discriminative performance of DCN-CS in NSCLC and IPF
Cut-off value (ng/mL) Sensitivity Specificity AUROC (95% CI) p-value
NSCLC vs. healthy controls 21.5 90.0 100.0 0.96 (0.90–0.99) <0.0001
IPF vs. healthy controls 8.9 62.9 82.7 0.77 (0.71–0.83) <0.0001
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lung cancer and IPF. The fact that the AUC was higher
for lung cancer compared to IPF, suggests that this
pathological event seems to be more associated with
lung cancer than IPF and DCN-CS could serve as a po-
tential diagnostic biomarker for lung cancer. In relation
to IPF, the data suggests other clinical uses of this bio-
marker, such as prognosis and/or prediction. This needs
to be further investigated in larger clinical studies. Evi-
dence suggests that decorin fragments can function as
pro-inflammatory signaling molecules, so-called damage-
associated molecular patterns (DAMPs), capable of in-
ducing an inflammatory response [5, 29]. High levels of
degraded decorin might therefore indicate a severe inflam-
matory state. However further studies are needed to investi-
gate whether the DCN-CS fragment functions as a DAMP.
The DCN-CS assay was shown to be technically robust,
with low values of LLOD, intra- and inter variation and
acceptable dilution recovery, interference and analyte sta-
bility at 4 °C. The fact that the assay did not detect the
elongated peptide nor a non-sense peptide indicates that
the monoclonal antibody is specific towards the cleavage
site between amino acid 74 and 75 located in the first
leucine-rich repeat of decorin. This was supported by data
showing that DCN-CS was able to quantify high levels of
the fragment after in vitro cleavage of decorin with Cat-S.
Reactivity towards intact decorin was minimal further
demonstrating that this assay does not measure total pro-
tein but a specific degraded fragment.
The target peptide fragment was originally identified
by Zhen et al. [23] in human articular cartilage digested
with ADAMTS-5. We have shown that this fragment is
generated by Cat-S and not by Cat-L, MMP-2/9 or
ADAMTS-5 in vitro using recombinant decorin. The
fact that ADAMTS-5 degradation could not generate
the target peptide fragment under our conditions, indi-
cates that other proteases may have to cleave the protein
before ADAMTS-5 can generate this fragment. Imai et
al. [30] have examined the ability of different MMP’-s to
cleave decorin and found that MMP-2, MMP-3 and
MMP-7 were able to generate degradation fragments.
None of these fragments correspond to our target frag-
ment which supports our findings that the DCN-CS frag-
ment is specifically generated by Cat-S and not MMP’s.
This is important since different protein fragments may
reflect different pathological events [31, 32], i.e. Cat-S
degraded decorin might reflect one disease state whereas
MMP-degraded decorin reflects other disease activity pat-
terns. As the present assay enables quantification of a spe-
cific neo-epitope it might be superior to other commercial
assays in which decorin is quantified but the precise epi-
tope is not known. These quantification capabilities also
increases the biomarker potential as it may reflect a direct
pathological event, such as fibrosis.
The diagnostic validation of DCN-CS in the present
study is limited by relatively small population sizes and
cross-sectional designs and clinical information was lim-
ited. In addition, it was not easy to match cases and con-
trols according to age, gender and tobacco consumption
in this preliminary study which therefore could be con-
founding factors. However the fact that we could confirm
the findings in independent cohorts, increases the validity.
Larger longitudinal studies are needed to fully validate the
potential of DCN-CS as a diagnostic and/or prognostic
biomarker in fibrotic lung diseases.
Conclusion
In conclusion, we have developed a technically robust
competitive ELISA assay targeting a specific Cat-S de-
graded fragment of decorin (DCN-CS). The level of
DCN-CS was significantly higher in patients with lung
cancer and IPF compared to healthy controls, suggesting
a pathological role of degraded decorin in these lung
disorders.
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